Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been recommended in several guidelines for the treatment of selected patients with peritoneal surface malignancies. As this is an aggressive strategy, many medical practitioners are concerned about the associated high mortality and morbidity figures, particularly if performed nationwide and not only in highly specialized centers.
PAST
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been recommended in several guidelines for the treatment of selected patients with peritoneal surface malignancies. As this is an aggressive strategy, many medical practitioners are concerned about the associated high mortality and morbidity figures, particularly if performed nationwide and not only in highly specialized centers. 1 To investigate this, we performed a retrospective analysis of prospective documented data from a large national registry, with a focus on morbidity and mortality following CRS and HIPEC.
PRESENT
For the first time, data from the German HIPEC Registry are reported, demonstrating that the concept of CRS and HIPEC is safe and can be performed with a low mortality. 2 Coming from a large national registry of more than 50 institutions, these data have a high relevance for the clinical routine practice of clinical oncologists. Moreover, the presented results show that CRS and HIPEC can be safely performed nationwide if close mentoring by experienced centers is provided. 3 
FUTURE
Registry data are associated with some bias, particularly in relation to missing data. 4 Therefore, data completion must become mandatory and must be reduced to essential parameters. The complete entered data must be verified by the quality manager of every involved center and should be part of a certification process, with an audit performed by a third-party auditor. The mentoring process is effective for new centers treating patients with CRS and HIPEC; however, for re-do procedures, recurrences, and high-risk patients, treatment in high-volume centers is recommended.
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